WALTHAM,
Mass., Dec. 18, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology
company utilizing best-in-class antibody engineering, rational
therapeutic combinations, and precision medicine approaches to
target improved efficacy and convenience in the treatment of
Inflammatory Bowel Disease ("IBD"), today announced Spyre has been
added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective
prior to market open, Monday, December 23,
2024.
The NBI is designed to track the performance of a set of
securities listed on The Nasdaq Stock
Market® that are classified as either biotechnology
or pharmaceutical according to the Industry Classification
Benchmark. Companies in the Nasdaq Biotechnology Index must
meet eligibility requirements, including minimum market
capitalization, average daily trading volume and seasoning as a
public company, among other criteria. The NBI is evaluated annually
in December and is calculated under a modified
capitalization-weighted methodology.
For more information about the Nasdaq Biotechnology Index,
please visit this link.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company
that aims to create next-generation inflammatory bowel disease
(IBD) products by combining best-in-class antibody engineering,
rational therapeutic combinations, and precision medicine
approaches. Spyre's pipeline includes extended half-life antibodies
targeting α4β7, TL1A, and IL-23. For more information, visit
Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and
LinkedIn
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-added-to-the-nasdaq-biotechnology-index-302334852.html
SOURCE Spyre Therapeutics, Inc.